Proteins and Peptides
PSMA Protein, Human, Recombinant (His Tag)
Proteins and Peptides
- 貨號 Cat. No.
- 15877-H07H
- 規格 Size
- 10 µg、50 µg
- 品牌 Brand
- Sino Biological
Description
Glutamate carboxypeptidase 2, also known as Glutamate
carboxypeptidase II, Membrane glutamate carboxypeptidase, Prostatespecific
membrane antigen, GCPII, PSMA, FOLH1, and NAALAD1, is a
single-pass type II membrane protein which belongs to thepeptidase M28
family and M28B subfamily. FOLH1 is highly expressed in prostate
epithelium. It is detected in urinary bladder, kidney, testis, ovary, fallopian
tube, breast, adrenal gland, liver, esophagus, stomach, small intestine,
colon, brain (at protein level), and the capillary endothelium of a variety of
tumors. FOLH1 has both folate hydrolase and N-acetylated alpha linked
acidic dipeptidase (NAALADase) activity. It has a preference for tri-alphaglutamate
peptides. Genetic variation in FOLH1 may be associated with
low folate levels and consequent hyperhomocysteinemia. This condition
can result in increased risk of cardiovascular disease, neural tube defects,
and cognitive deficits. FOLH1 also shows a promising role in directed
imaging and therapy of recurrent or metastatic disease.
carboxypeptidase II, Membrane glutamate carboxypeptidase, Prostatespecific
membrane antigen, GCPII, PSMA, FOLH1, and NAALAD1, is a
single-pass type II membrane protein which belongs to thepeptidase M28
family and M28B subfamily. FOLH1 is highly expressed in prostate
epithelium. It is detected in urinary bladder, kidney, testis, ovary, fallopian
tube, breast, adrenal gland, liver, esophagus, stomach, small intestine,
colon, brain (at protein level), and the capillary endothelium of a variety of
tumors. FOLH1 has both folate hydrolase and N-acetylated alpha linked
acidic dipeptidase (NAALADase) activity. It has a preference for tri-alphaglutamate
peptides. Genetic variation in FOLH1 may be associated with
low folate levels and consequent hyperhomocysteinemia. This condition
can result in increased risk of cardiovascular disease, neural tube defects,
and cognitive deficits. FOLH1 also shows a promising role in directed
imaging and therapy of recurrent or metastatic disease.